Oncology



Cancer, rising to the challenge

Life is a health journey and we, at Sanofi, are committed to finding therapeutic solutions for the millions of people who are or will be concerned by cancer.  The number of cancer cases is expected to grow dramatically over the next two decades.

As a health journey partner, we, at Sanofi, are rising to the challenge.  We are committed to fighting cancer through early detection and treatments, including pain relief and palliative care.  Sanofi Genzyme, our global specialty care business unit, has innovative treatments under development and is exploring innovative pathways to fight cancer.
Infographics on Cancers  Infographics on Cancers

Understanding cancer

Whereas healthy cells divide in the body in an organized way, cancer is caused by the erratic division and growth of cells in the body. Cancer can start in any part of the body and spread to other parts.

Cancer is not one single disease and the World Health Organization (WHO) estimates that there are more than 100 different kinds of cancer, each with specific treatment needs.

As a health journey partner, we are strongly engaged in the fight against cancer and we are committed to provide patients, including those of emerging markets1, with healthcare solutions. We have a strong presence in prostate cancer and have several late stage research programs in areas such as multiple myeloma and cutaneous squamous cell carcinoma.

Exploring new pathways through open innovation

We, at Sanofi, believe that open innovation will help develop new approaches and expertise to discover targeted treatments against cancer.

As a health journey partner, we partner with academic research teams, biotech companies and specialized cancer centers, to foster innovation in cancer treatments.

Some of our current collaborations with Warp Drive Bio, Evotec, Apeiron Biologis, Regeneron Pharmaceuticals and Innate Pharma, focus on understanding how the immune system itself can be boosted to recognize and eliminate cancer cells – a field known as immuno-oncology.


(1)Emerging markets: world excluding U.S., Canada, Western Europe (France, Germany, UK, Italy, Spain, Greece, Cyprus, Malta, Belgium, Luxembourg, Portugal, the Netherlands, Austria, Switzerland, Sweden, Ireland, Finland, Norway, Iceland, Denmark), Japan, South Korea, Australia and New Zealand.